Anti-androgen

Phase 3Small molecule

Radiation Therapy Oncology Group

Anti-androgen is one of 66 small molecule programs targeting Salivary Gland Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Salivary Gland CancerActive, not recruiting

Prostate CancerActive, not recruiting

Salivary Gland CancerPreclinical

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Anti-androgen

Radiation Therapy Oncology Group

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT01546987·239 enrolled

Salivary Gland Cancer1 trial

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Completed·UUniversity Health Network, Toronto·N/A·NCT02069730·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-androgen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-androgen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-androgen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radiation Therapy Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Radiation Therapy Oncology Group

Anti-androgen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer1 trial

Salivary Gland Cancer1 trial

References

Drug Info

Quick Facts

Related News